A randomized controlled double-blind study on the brain protection of infantile patients with epileptic spasm syndrome through atomized inhalation of hydrogen-oxygen gas.
Chen C, He W, Chen J, Shi XY, Yang G, Wang J, Wang YY, Hu PL, Han F, Meng Y, Zou LP · Frontiers in neurology · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
The study adds to the molecular-hydrogen evidence base, but the available record does not support a firm conclusion about therapeutic benefit.
Oxyhydrogen cardiovascular health study 2026: what the findings mean
This H2HUBB page translates the technical study record into consumer-friendly language while preserving the scientific details. Hydrogen-oxygen nebulization inhalation has a brain-protective effect. This study aims to evaluate its short-term efficacy and safety as an adjuvant treatment for infantile epileptic spasms syndrome (IESS). A prospective randomized double-blind controlled trial enrolled 53 IESS children (Nov 2021-Nov 2023), randomized via a random number table into a hydrogen-oxygen inhalation group (27 cases, 66.6% H₂/33.3% O₂ nebulization) and an air inhalation group (26 cases, medical air nebulization).
Publication: Chen C, He W, Chen J, Shi XY, Yang G, Wang J, Wang YY, Hu PL, Han F, Meng Y, Zou LP, Frontiers in neurology, 2026.
What the researchers studied
Hydrogen-oxygen nebulization inhalation has a brain-protective effect. This study aims to evaluate its short-term efficacy and safety as an adjuvant treatment for infantile epileptic…
What effects did molecular hydrogen have?
Observed hydrogen effects: Hydrogen-oxygen nebulization inhalation has a brain-protective effect. There was no statistically significant difference.
Why these findings matter
The available record suggests a reason to continue studying hydrogen, but it does not provide enough information for a firm therapeutic conclusion.
How strong is this evidence?
This is direct human evidence from a randomized trial, which is generally more informative about treatment effects than an uncontrolled report. Randomization: Yes. Blinding: Double-blind.
Technical study details
- Publication type: Randomized controlled trial
- Evidence type: Human clinical evidence
- Research model or population: Pediatric human participants
- Randomized: Yes
- Blinding: Double-blind
- Hydrogen method: Oxyhydrogen
Limitations and safety
Important limitations: The abstract alone may not report all methodological limitations; full-text review is required.
Safety information: This study aims to evaluate its short-term efficacy and safety as an adjuvant treatment for infantile epileptic spasms syndrome (IESS).
Original study and H2HUBB research context
This page explains a published research record and does not turn one study into a medical recommendation. Read the original scientific source for the complete methods, statistics, and author conclusions. Compare this result with related evidence in the H2HUBB Molecular Hydrogen Research Library.